{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:05Z","timestamp":1788791345710,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00115-026-02001-1","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:57:07Z","timestamp":1786971427000},"page":"504-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["(Es\u2011)Ketamin: Praxis-Update","(Es)ketamine: practice update"],"prefix":"10.1007","volume":"97","author":[{"given":"Stefan","family":"Vestring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Domschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Normann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2001_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman\u00a0RM, Cappiello\u00a0A, Anand\u00a0A et\u00a0al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351\u2013354","journal-title":"Biol Psychiatry"},{"key":"2001_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate\u00a0CA, Singh\u00a0JB, Carlson\u00a0PJ et\u00a0al (2006) A Randomized Trial of an N\u2011methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Arch Gen Psychiatry 63:856\u2013864. https:\/\/doi.org\/10.1001\/archpsyc.63.8.856","journal-title":"Arch Gen Psychiatry"},{"key":"2001_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41386-023-01632-1","volume":"49","author":"JN Johnston","year":"2024","unstructured":"Johnston\u00a0JN, Kadriu\u00a0B, Kraus\u00a0C et\u00a0al (2024) Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology 49:23\u201340. https:\/\/doi.org\/10.1038\/s41386-023-01632-1","journal-title":"Neuropsychopharmacol"},{"key":"2001_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bdi.13296","volume":"25","author":"G Martinotti","year":"2023","unstructured":"Martinotti\u00a0G, Dell\u2019Osso\u00a0B, Di Lorenzo\u00a0G et\u00a0al (2023) Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord 25:233\u2013244. https:\/\/doi.org\/10.1111\/bdi.13296","journal-title":"Bipolar Disord"},{"key":"2001_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/20451253251394127","volume":"15","author":"A Elmosalamy","year":"2025","unstructured":"Elmosalamy\u00a0A, Tarikogullari\u00a0I, Patarroyo-Rodriguez\u00a0L et\u00a0al (2025) Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Ther Adv Psychopharmacol 15:20451253251394127. https:\/\/doi.org\/10.1177\/20451253251394127","journal-title":"Ther Adv Psychopharmacol"},{"key":"2001_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos\u00a0P, Gould\u00a0TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23:801\u2013811. https:\/\/doi.org\/10.1038\/mp.2017.255","journal-title":"Mol Psychiatry"},{"key":"2001_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00115-021-01221-x","volume":"93","author":"S Vestring","year":"2022","unstructured":"Vestring\u00a0S, Domschke\u00a0K, Normann\u00a0C (2022) Ketamine and other N\u2011methyl-D-aspartate receptor modulators in treatment of depression. Nervenarzt 93:234\u2013242. https:\/\/doi.org\/10.1007\/s00115-021-01221-x","journal-title":"Nervenarzt"},{"key":"2001_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66774-w","volume":"16","author":"S Vestring","year":"2025","unstructured":"Vestring\u00a0S, Veleanu\u00a0M, Perez\u00a0MC et\u00a0al (2025) The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action. Nat Commun 16:10613. https:\/\/doi.org\/10.1038\/s41467-025-66774-w","journal-title":"Nat Commun"},{"key":"2001_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat8078","volume":"364","author":"RN Moda-Sava","year":"2019","unstructured":"Moda-Sava\u00a0RN, Murdock\u00a0MH, Parekh\u00a0PK et\u00a0al (2019) Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364:eaat8078. https:\/\/doi.org\/10.1126\/science.aat8078","journal-title":"Science"},{"key":"2001_CR10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto\u00a0PC, Girych\u00a0M, Fred\u00a0SM et\u00a0al (2021) Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Device 184:1299\u20131313.e19. https:\/\/doi.org\/10.1016\/j.cell.2021.01.034","journal-title":"Cell"},{"key":"2001_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1126\/science.adt1480","volume":"386","author":"E Castr\u00e9n","year":"2024","unstructured":"Castr\u00e9n\u00a0E, Normann\u00a0C (2024) FDA should consider drug-therapy regimens. Science 386:1356\u20131357. https:\/\/doi.org\/10.1126\/science.adt1480","journal-title":"Science"},{"key":"2001_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-023-06624-1","volume":"622","author":"S Ma","year":"2023","unstructured":"Ma\u00a0S, Chen\u00a0M, Jiang\u00a0Y et\u00a0al (2023) Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb. Nat Cell Biol 622:802\u2013809. https:\/\/doi.org\/10.1038\/s41586-023-06624-1","journal-title":"Nature"},{"key":"2001_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-025-09755-9","volume":"649","author":"C Yue","year":"2026","unstructured":"Yue\u00a0C, Wang\u00a0N, Zhai\u00a0H et\u00a0al (2026) Adenosine signalling drives antidepressant actions of ketamine and ECT. Nat Cell Biol 649:423\u2013431. https:\/\/doi.org\/10.1038\/s41586-025-09755-9","journal-title":"Nature"},{"key":"2001_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1126\/science.abb6748","volume":"388","author":"ZZ Ma","year":"2025","unstructured":"Ma\u00a0ZZ, Guzikowski\u00a0NJ, Kim\u00a0JW et\u00a0al (2025) Enhanced ERK activity extends ketamine\u2019s antidepressant effects by augmenting synaptic plasticity. Science 388:646\u2013655. https:\/\/doi.org\/10.1126\/science.abb6748","journal-title":"Science"},{"key":"2001_CR15","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","volume":"389","author":"A Reif","year":"2023","unstructured":"Reif\u00a0A, Bitter\u00a0I, Buyze\u00a0J et\u00a0al (2023) Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N Engl J Med 389:1298\u20131309. https:\/\/doi.org\/10.1056\/NEJMoa2304145","journal-title":"N Engl J Med"},{"key":"2001_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jad.2024.01.165","volume":"350","author":"S Vestring","year":"2024","unstructured":"Vestring\u00a0S, Galuba\u00a0V, Kern\u00a0E et\u00a0al (2024) Ketamine in multiple treatment-resistant depressed inpatients: A naturalistic cohort study. J\u00a0Affect Disord 350:895\u2013899. https:\/\/doi.org\/10.1016\/j.jad.2024.01.165","journal-title":"J Affect Disord"},{"key":"2001_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ijnp\/pyab039","volume":"24","author":"JKE Veraart","year":"2021","unstructured":"Veraart\u00a0JKE, Smith-Apeldoorn\u00a0SY, Bakker\u00a0IM et\u00a0al (2021) Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Int J Neuropsychopharmacol 24:808\u2013831. https:\/\/doi.org\/10.1093\/ijnp\/pyab039","journal-title":"Int J Neuropsychopharmacol"},{"key":"2001_CR18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapsychiatry.2025.1317","volume":"82","author":"A Janik","year":"2025","unstructured":"Janik\u00a0A, Qiu\u00a0X, Lane\u00a0R et\u00a0al (2025) Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 82:877\u2013887. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.1317","journal-title":"JAMA Psychiatry"},{"key":"2001_CR19","doi-asserted-by":"crossref","unstructured":"de Oliveira Lapa C, Viola T, Delfino R et\u00a0al. (2026) Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies. J\u00a0Affect Disord 401:121257. https:\/\/doi.org\/10.1016\/j.jad.2026.121257","DOI":"10.1016\/j.jad.2026.121257"},{"key":"2001_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/20420986251347360","volume":"16","author":"G Gutierrez","year":"2025","unstructured":"Gutierrez\u00a0G, Vazquez\u00a0G, Ravindran\u00a0N et\u00a0al (2025) Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee. Ther Adv Drug Saf 16:20420986251347360. https:\/\/doi.org\/10.1177\/20420986251347360","journal-title":"Ther Adv Drug Saf"},{"key":"2001_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241310685","volume":"16","author":"C Roncero","year":"2025","unstructured":"Roncero\u00a0C, Merizalde-Torres\u00a0M, Szerman\u00a0N et\u00a0al (2025) Is there a risk of esketamine misuse in clinical practice? Therapeutic Advances in Drug Safety 16:20420986241310685. https:\/\/doi.org\/10.1177\/20420986241310685","journal-title":"Therapeutic Advances in Drug Safety"},{"key":"2001_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","volume":"74","author":"S Chiappini","year":"2023","unstructured":"Chiappini\u00a0S, d\u2019 Andrea\u00a0G, De Filippis\u00a0S et\u00a0al (2023) Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol 74:15\u201321. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.04.011","journal-title":"Eur Neuropsychopharmacol"},{"key":"2001_CR23","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2023) Schulungsmaterial f\u00fcr Patienten: Esketamin (Spravato)."},{"key":"2001_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146673","volume":"26","author":"S Sakopoulos","year":"2025","unstructured":"Sakopoulos\u00a0S, Todman\u00a0M (2025) The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment. International Journal of Molecular Sciences 26:6673. https:\/\/doi.org\/10.3390\/ijms26146673","journal-title":"International Journal of Molecular Sciences"},{"key":"2001_CR25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","volume":"388","author":"A Anand","year":"2023","unstructured":"Anand\u00a0A, Mathew\u00a0SJ, Sanacora\u00a0G et\u00a0al (2023) Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine 388:2315\u20132325. https:\/\/doi.org\/10.1056\/NEJMoa2302399","journal-title":"New England Journal of Medicine"},{"key":"2001_CR26","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1097\/YCT.0000000000001034","volume":"40","author":"D Zilles-Wegner","year":"2024","unstructured":"Zilles-Wegner\u00a0D, Kellner\u00a0CH, Sartorius\u00a0A (2024) Electroconvulsive Therapy and Its New Competitors: ECT Remains the Gold Standard. J\u00a0ECT 40:e31\u2013e32. https:\/\/doi.org\/10.1097\/YCT.0000000000001034","journal-title":"J ECT"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-02001-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-02001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:52:04Z","timestamp":1788789124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-02001-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-02001-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Vestring\n                      : A.\u00a0Finanzielle Interessen: F\u00f6rderung durch die medizinische Fakult\u00e4t Freiburg (Berta-Ottenstein Programm), BMBF (Bundesministeriums f\u00fcr Bildung und Forschung; Go-Bio initial Sondierungs- und Machbarkeitsphase), Else-Kr\u00f6ner-Fresenius Stiftung (ForTra), DFG (Deutsche Forschungsgemeinschaft) und ERA-NET(Netzwerk Europ\u00e4ischer Forschungsf\u00f6rderung f\u00fcr Neurowissenschaften)-Neuron.\u00a0\u2013 Vortragshonorare sowie die gef\u00f6rderte Kongressteilnahme (Anreise, \u00dcbernachtung, Verpflegung sowie Kongressteilnahmegeb\u00fchren) von Johnson & Johnson, dem Hersteller von Spravato (Esketamin).\u00a0\u2013 Berater f\u00fcr Cumulus Neuroscience, dem Hersteller von Neulogiq, einer Plattform zum Assessment synaptischer Plastizit\u00e4t beim Menschen (Einsatz in klinischen Studien im Bereich Neurodegeneration und affektive St\u00f6rungen). Referent am FAVT (Freiburger Ausbildungsinstitut f\u00fcr Verhaltenstherapie).\u00a0\u2013 Miterfinder eines angemeldeten Patentes der Albert-Ludwigs-Universit\u00e4t Freiburg zur Verwendung von GluN2D-Inhibitoren in der Behandlung der Depression (EP\u00a022153076.9\/WO 2023\/144163), dem angenommenen Wirkmechanismus von Ketamin.\u00a0\u2013 B. Nichtfinanzielle Interessen: Funktionsoberarzt der Stimulations- und Schlaf-Unit an der Universit\u00e4tsklinik Freiburg (Behandlungsfokus: therapieresistente Depression).\u00a0| Mitglied der DGPPN (Deutsche Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.\u202fV.) und hier speziell des Referats Hirnstimulation. | Zertifizierter IPT-Psychotherapeut (interpersonelle Psychotherapie) und Mitglied der DG-IPT (Deutsche Gesellschaft f\u00fcr Interpersonelle Psychotherapie). | Dozent am FAVT (Freiburger Ausbildungsinstitut f\u00fcr Verhaltenstherapie).\n                      K.\u00a0Domschke\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare Janssen-Cilag GmbH, ROVI; (Es\u2011)Ketamin: Praxis-Update.\u00a0\u2013 Janssen Inc.; Neurotorium Editorial Board, Lundbeck.\u00a0\u2013 B. Nichtfinanzielle Interessen: \u00c4rztliche Direktorin Klinik f\u00fcr Psychiatrie und Psychotherapie, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: Vorstand DGPPN, Vorstand FAVT, Neurotorium Editorial Board, Lundbeck.\n                      C.\u00a0Normann:\n                      A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: DFG, BMBF (GO-Bio initial), Else Kr\u00f6ner-Fresenius-Stiftung\/ForTra gGmbH.\u00a0\u2013 Vortragshonorare Janssen-Cilag, Kongressteilnahme: Janssen-Cilag, Boehringer.\u00a0\u2013 Advisory Board\/Beratungsleistungen Janssen-Cilag, Boehringer, Cumulus Neuroscience, Novartis (DMC), Precisis; Schulung: FAVT (Freiburger Ausbildungsinstitut f\u00fcr Verhaltenstherapie).\u00a0\u2013 Erfinder Patent WO 2023\/144163, GluN2D-Antagonisten zur Behandlung der Depression (Universit\u00e4t Freiburg).\u00a0\u2013 B. Nichtfinanzielle Interessen: Gesch\u00e4ftsf\u00fchrender Oberarzt\/Sektionsleiter Psychiatrie Uniklinik Freiburg | Mitgliedschafen: DGPPN, ECNP (European College of Neuropsychopharmacology), DG-IPT, CBASP(Cognitive Behavioral Analysis System of Psychotherapy)-Network e.\u202fV.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}